Give them a fighting chance.

In the US, 22% of patients diagnosed with cancer hear the word ‘rare’ and are faced with a probable death sentence. That’s almost 1 in 4.
But we can change that.

Hope beyond cancer

Our mission is to fundamentally shift how all cancers – including rare and resistant (RARE) tumors – are treated. Through pioneering research and rapid integration into clinical trials, The RARE Initiative can bring real hope to those with limited treatment options.
Working together with a vast network of scientists, translational researchers, bioinformatics specialists and mathematics modeling experts, our oncologists are committed to deeply understanding cancer biology. Why do only some tumors respond? Why do some treatments stop working?
Answering these questions and finding solutions is the focus of The Rare Initiative; a dedicated team of experts primed and perfectly positioned to develop best-in-class and first-in-class precision medicines for patients who need it most.

Leading the way with precision oncology

The Henri and Belinda Termeer Center for Targeted Therapies is a pioneer in developing genetically-targeted cancer therapies. The Center is comprised of highly talented investigators and clinicians, active in Mass General Hospital’s 29 treatment programs as well as caring for patients. The Termeer Center’s primary goal is to uncover the underlying causes of cancer and identify new targets for precision oncology.

Pioneering treatment options made possible.

Perfectly placed in the heart of the largest research universe in life sciences, close to Harvard University, MIT, pioneering biotech startups and global pharmaceutical companies, we are able to share our expertise and expand research alliances in a way others can’t, shortening the time it takes to discover and deliver innovative treatments to patients. When our discoveries reveal promising possibilities for treatment, we bring them directly to our patients in the clinic.

With your support, we can make a real difference.

Rare tumors account for 22% of all cancers and are more difficult to prevent, diagnose and treat than others. Drug development is notoriously slow and finding enough patients able to take part in clinical trials is an ongoing challenge. Rare and Resistant cancers garner little attention from scientific communities, pharmaceutical companies and funding agencies but with your help, we can take action ourselves.
Our primary goal centers around 3 main projects:

Tumor Heterogeneity and Drug Resistance in Cholangiocarcinoma.

– Read more

PIK3CA Clear Cell Carcinoma of the Ovary.

– Read more

Personalized Immunotherapy.

– Read more

I want to make a difference

Donate